Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The Oral Polio Vaccine (OPV) is genetically unstable and may mutate to form vaccinederived polioviruses (VDPVs). At present, the finding of VDPV mainly come from AFP surveillance and environmental sewage surveillance.
Methods: In 2023, a vaccine-derived poliovirus (VDPV) strain type 3 isolated from a patient with hand, foot, and mouth disease (HFMD) in Guangdong Province, China, was sequenced and analyzed.
Result: The strain had reversion mutations at the known attenuation site 5' non-coding region and recombined with Sabin1, Phylogenetic analysis of the VP1 coding region showed that the Guangdong type 3 VDPV evolved independently of other type 3 VDPVs found globally.
Conclusion: It is meaningful to increase the sensitivity of surveillance of other enteroviral diseases for polioviruses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205517 | PMC |
| http://dx.doi.org/10.1186/s12985-025-02827-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-grade persistent poliovirus infection in long-term polio survivors diagnosed with post-polio syndrome: diagnostic and clinical implications.
J Neurol
September 2025
Department of Neurological, Neuropsychological, Morphological and Motor Sciences, University of Verona Medical School, 37134, Verona, Italy.
Despite extensive research, the pathogenesis of Post-Polio Syndrome (PPS) remains unclear. We investigated 251 participants from Northern Italy: long-term polio survivors with PPS, long-term polio survivors with stable polio, family members of both groups, subjects with neurological disorders other than poliomyelitis, and healthy controls. This study investigated whether persistent viral activity or the existence of viral reservoirs contributes to causing PPS.
View Article and Find Full Text PDFIntestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newborns.
Clin Infect Dis
September 2025
Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth Health, Lebanon, New Hampshire, USA.
Background: Approximately 1.5 billion doses of novel oral polio vaccine type 2 (nOPV2) have been administered in response to circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks since 2021. Although infants are eligible to receive the vaccine from birth, the induction of intestinal mucosal immunity by nOPV2 in newborns has not been directly evaluated.
View Article and Find Full Text PDFEarly detection of a circulating pre-vaccine-derived poliovirus type 1 (pre-VDPV1) variant linked to an acute flaccid polio case prior to VDPV1 emergence, Israel, 2024 to 2025.
Euro Surveill
August 2025
Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan, Israel.
We report the emergence and evolution of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak in Israel, linked to a vaccine-associated paralytic poliomyelitis case. Whole genome sequencing revealed a strong genetic link between the Sabin-like poliovirus type 1 variant from the case and pre-VDPV1 and VDPV1 isolated from environmental samples collected in October 2024-April 2025, mostly in Jerusalem. Early detection was made possible by Israel's robust environmental surveillance and advanced sequencing technologies, enabling a rapid public health response.
View Article and Find Full Text PDFSafety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial.
Lancet Infect Dis
August 2025
Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA. Electronic address:
Background: Reducing the risks of vaccine-derived polioviruses and vaccine-associated paralytic poliomyelitis motivated the development of novel types 1 and 3 oral poliovirus vaccines (nOPV1 and nOPV3, respectively), designed to have similar safety and immunogenicity and improved genetic stability (to reduce risk of reversion to neurovirulence) relative to types 1 or 3 Sabin-strain OPVs. We aimed to assess the safety and immunogenicity of nOPV1 and nOPV3 in healthy adults.
Methods: We did a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial in healthy adults at four centres in the USA.
Characteristics of four natural poliovirus type 1 variants with six-nucleotide deletion (2,783-2,788 nt) in the VP1 region.
Microbiol Spectr
September 2025
National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prev
Since the establishment of the Chinese acute flaccid paralysis (AFP) case surveillance system in 1999, around 7,200 strains of poliovirus (PV) type 1 have been identified and isolated. Among these, the VP1 region of 5,649 strains has been sequenced. Based on the existing VP1 region sequence library, four strains of type 1 PV with six-nucleotide deletion in the VP1 region, identified from AFP cases, healthy children, and environmental sewage samples, were identified, and their biological characteristics were investigated.
View Article and Find Full Text PDF